SBI Holdings Of Japan To License Antibodies To AstraZeneca
This article was originally published in PharmAsia News
Executive SummaryJapan's SBI Holdings plans to sell its antibody-drug rights to U.K.-based AstraZeneca to develop and market. SBI Holdings is a venture capital firm that owns SBI Biotech, and expects to earn about $94.7 million from the drug. AstraZeneca's Medimmune is to conduct the clinical trials on drugs for lupus and other autoimmune disorders. SBI hopes to take advantage of AstraZeneca's global presence to get the drug to market. (Click here for more - a subscription may be required
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.